PARIS: Two vaccine candidates stumbled Friday in the race among researchers to combat Covid-19, a setback for the global immunisation effort even as the Pfizer-BioNTech jab neared approval in the US. The mixed news on the vaccine front comes as infections accelerated fast in North America and parts of Africa but started to stabilise in Europe and drop in Asia and the Middle East.
Around the world more than 1.58 million lives have been lost to Covid-19 since it emerged in China a year ago, according to an AFP tally from official sources. While the record-fast development of vaccine options has brought hope to the planet, some candidates are suffering setbacks.
France's Sanofi and Britain's GSK said on Friday their vaccine would not be ready until the end of 2021. New results showed a low immune response in older adults, researchers said.
And in Australia, the development of a vaccine in phase one trials at The University of Queensland was abandoned Friday after clinical trials produced a false positive HIV result among subjects involved in early-stage testing.
Yet inoculation plans with other vaccines are picking up pace. In the US, an expert recommendation on Pfizer means the shot will likely receive official approval from the US Food and Drug Administration (FDA) in a matter of days. President-elect Joe Biden hailed the "bright light in a needlessly dark time" in the US, which is home to the world's highest death toll at nearly 300,000.
The country hopes to start vaccinating 20 million people this month, starting with long-term care facility residents and health workers. Britain this week became the first Western country to roll out the Pfizer-BioNTech jab, which Canada, Bahrain and Saudi Arabia have also approved.
The first vaccine shipments to 14 sites across Canada are scheduled to arrive Monday with people receiving shots a day or two later. Israel, which accepted its first shipment of the Pfizer vaccine on Wednesday, is targeting a rollout on December 27. And Hong Kong said Friday it had struck deals for two vaccines - one from Pfizer and the other from Beijing-based Sinovac - with plans to launch a campaign in early 2021.
A new combined approach is also being tested by AstraZeneca, whose Russian operation said it would mix its shot with the locally-made Sputnik V vaccine in clinical trials.
"Combinations of different Covid-19 vaccines may be an important step in generating wider protection through a stronger immune response and better accessibility," the pharma giant said in its statement.
Russia and China have already begun inoculation efforts with domestically produced vaccines that have seen less rigorous vetting, while EU countries are eagerly awaiting clearance on two options. The EU's watchdog said it would deliver decisions on the Pfizer and Moderna vaccines in late December and early January respectively.